Sickle Cell Disease and Sickle Cell Anaemia

oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

Sickle cell haemoglobin (HbS) results from an autosomal recessively inherited mutation in which the 17th nucleotide of the beta globin gene is changed from thymine to adenine and the amino acid glutamic acid is replaced by valine at position 6 in the beta globin chain.[1] Sickle cells have a reduced deformability and are easily destroyed, causing occlusion of the microcirculation and a chronic haemolytic anaemia with a median haemoglobin concentration level of about 9 g/dL.[2] Sickling disorders include heterozygous (AS) sickle cell trait, homozygous (SS) sickle cell disease, compound heterozygous states for HbS with haemoglobins C, D, E, or other structural variants and the combination of the sickle cell gene with different forms of thalassaemia.

Sickle cell disease refers to the group of disorders that affects haemoglobin to form abnormal haemoglobin molecules (HbS). Sickle cell anaemia is the name of the specific form of sickle cell disease in which there is homozygosity for the mutation that causes HbS (ie HBSS).

The major sickle genotypes are:[3]

  • HbSS disease or sickle cell anaemia: homozygote for the beta S globin with usually a severe or moderately severe phenotype.
  • HbS/beta0 thalassaemia: severe double heterozygote for HbS and beta0 thalassaemia, and almost clinically indistinguishable from sickle cell anaemia.
  • HbSC disease: double heterozygote for HbS and HbC with intermediate clinical severity.
  • HbS/beta+ thalassaemia: mild-to-moderate severity, but variable in different ethnic groups.
  • HbS/hereditary persistence of fetal Hb (S/HPHP): symptom-free.
  • HbS/HbE syndrome: very rare and generally very mild clinical course.
  • Rare combinations of HbS with HbD Los Angeles, HbO Arab, G-Philadelphia, among others.

Clinical severity of sickle cell disease is very variable: a minority have few complications and their disease is clinically unapparent; a majority have intermediate forms, and another minority have severe complications including sepsis, strokes, recurrent painful episodes, acute chest syndrome, pulmonary hypertension and priapism.[2]

NEW - log your activity

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »
  • Heterozygotes; there is typically 60% HbA and 40% HbS. Sickle cell trait protects against malaria.
  • Sickle cell trait occurs in approximately 300 million people worldwide, with the highest prevalence of approximately 30% to 40% in sub-Saharan Africa.
  • People with sickle cell trait are generally asymptomatic and have no abnormal physical findings. However, sickle cell trait is occasionally associated with significant morbidity, eg haematuria, decreased ability to concentrate urine, renal papillary necrosis, splenic infarction, exertional rhabdomyolysis and exercise-related sudden death. Sickle cell trait is also associated with rare but often fatal renal medullary cancer.
  • Despite the associated morbidity, the average lifespan of individuals with sickle cell trait is similar to that of the general population.
  • Laboratory tests are normal with no anaemia, no evidence of haemolysis, and no laboratory abnormalities other than the presence of haemoglobin AS on haemoglobin electrophoresis.
  • Sudden death may be induced by severe hypoxia (including flying in unpressurised aircraft, visiting very high altitudes or problems during general anaesthesia), severe dehydration and severe physical exertion.[5]
  • Adequate hydration, avoidance of excessive fluid loss and avoiding severe heat are very important to help prevent complications such as exertional heat injury, splenic infarction, pain episodes and sudden death.
  • Those people with sickle cell trait who participate in sporting activities should be advised to build up slowly in training with paced progressions, allowing longer periods of rest and recovery between repetitions. Pre-season strength and sports-specific conditioning programmes should be encouraged.[5]
  • About 10,000 people in the UK have sickle cell disease.[2]
  • The prevalence of sickle-cell disease is highest in sub-Saharan Africa.[1] The sickle beta globin gene is spread widely throughout Africa, the Middle East, Mediterranean and India (eg sickle genes are present in 1 in every 50 Asians and 1 in every 100 Northern Greeks). The gene has spread through population movement to the Caribbean, North America and Northern Europe.
  • The frequency of sickle cell carriers is up to 1 in 4 in West Africans and 1 in 10 in Afro-Caribbeans. There is evidence for partial resistance of carriers to all forms of Plasmodium falciparum malaria in many populations.[1]

Presentation

The symptoms of sickle cell disease can begin between 3 months and 6 months of age when HbF levels are falling.

  • Anaemia, jaundice, pallor, lethargy, growth restriction and general weakness; the most common causes of anaemia are acute splenic sequestration, transient red cell aplasia, and hyperhaemolysis in patients with severe infection.[2]
  • Increased susceptibility to infections by encapsulated bacteria such as pneumococcus; the risk of overwhelming infection is highest before the age of 3 years.[2]
  • Splenomegaly may be present in infancy and childhood but recurrent splenic infarcts then cause autosplenectomy.
  • Delayed puberty.
  • Vaso-occlusive crises (obstruction of the microcirculation by sickled red blood cells, causing ischaemia):
    • This is the most common type of crisis. It may be precipitated by cold, infection, dehydration, exertion or ischaemia. Often no specific cause can be found.
    • Occlusion of small vessels by sickled erythrocytes causes pain which is variable from mild to severe. May present with swollen painful joints, tachypnoea or other signs of lung involvement, neurological signs, acute abdominal distension and pain (mesenteric sickling and bowel ischaemia), loin pain (renal papillary necrosis may cause renal colic or severe haematuria), priapism, hyphaema and retinal occlusion.
    • Large vessels may also be involved, causing thrombotic strokes, acute sickle chest syndrome and placental infarction.
    • Stroke:
      • Variable presentation, including fits and focal neurological signs.
      • Cerebral infarction is more common in children.
      • Haemorrhage from microaneurysms which develop around infarctions ('moyamoya') is more common in adults.
  • Aplastic crisis (temporary cessation of erythropoiesis, causing severe anaemia):[6]
    • Usually precipitated by infection with parvovirus B19.
    • There is usually a drop in haemoglobin over about one week.
    • Recovery may be spontaneous but a transfusion is usually required.
    • With the severe anaemia associated with an aplastic crisis, patients may present with high-output congestive heart failure.
  • Sequestration crisis (sudden enlargement of the spleen, causing a decrease in haemoglobin concentration, circulatory collapse and hypovolaemic shock):
    • Occurs mainly in babies and young children. The severity is variable but can present with shock and anaemia.[3]
    • Acute splenic sequestration has been defined as an acute fall of haemoglobin and markedly elevated reticulocyte count, together with an acute increase in spleen size.[6]
    • If unrecognised, sequestration causes significant mortality. Mortality rates can be reduced substantially by parental education, regular palpation of the abdomen at home to detect early signs of splenic enlargement, and prompt transfusion.[6]
    • Recurrent splenic sequestration is an indication for splenectomy.[6]
  • Acute chest syndrome (vaso-occlusive crisis affecting the lungs):
    • Defined as a new pulmonary infiltrate on the chest radiograph combined with one or more manifestations such as fever, cough, sputum production, tachypnoea, dyspnoea, or new-onset hypoxia.
    • Lung infections tend to predominate in children, and infarcts predominate in adults.
  • Hyperhaemolytic crisis (excessive haemolysis): uncommon; during painful crises there may be a marked increase in the rate of haemolysis with a fall in the haemoglobin level.

Other causes of haemolytic anaemia.

  • FBC and blood film: the haemoglobin level is in the range 6-8 g/dL with a high reticulocyte count of 10-20%; the blood films may show sickled erythrocytes and features of hyposplenism.
  • Sickling of red cells on a blood film with 2% sodium metabisulphite.
  • Sickle solubility test: a mixture of HbS in a reducing solution such as sodium dithionite gives a turbid appearance because of precipitation of HbS, whereas normal haemoglobin gives a clear solution.
  • Haemoglobin analysis, eg by electrophoresis, is always needed to confirm the diagnosis. There is no HbA, 80-95% HbSS, and 2-20% HbF.
  • Sickle cell trait is diagnosed by the finding of a positive sickling test together with haemoglobins A and S on electrophoresis.

Other investigations such as renal function tests, LFTs and lung function tests should also be performed at diagnosis (baseline) and routine monitoring. Other investigations will depend on any complications, eg infection screen, abdominal ultrasound, CT scan of the head (eg if a subarachnoid haemorrhage is suspected).[7]

  • Preconceptual testing for haemoglobinopathies is recommended in at-risk groups.[8]
  • Policies for antenatal and neonatal screening vary throughout the UK (see link to UK Screening Portal under 'Document references, below, for further information).[9]
  • Preoperative screening for sickle cell disease should be carried out in patients from ethnic groups in which there is a significant prevalence of the condition. Emergency screening with sickle solubility tests must always be followed by definitive analysis.[8]
  • Prenatal diagnosis: sickle cell disease can also be diagnosed in a fetus through prenatal diagnosis (following genetic counselling) from amniocentesis, chorionic villus sampling and fetal blood sampling.[2][10]

National haemoglobinopathy cards are available for affected, carrier and normal individuals following haemoglobinopathy screening. It is considered good practice to issue haemoglobinopathy cards to those with a major haemoglobinopathy and also to carriers where a definitive diagnosis can be made.[8]

It is very important that people with sickle cell disease should be reviewed regularly at a specialist centre; non-specialist hospitals should contact the nearest specialist centre when treating patients with sickle cell disease.[6] Patients should be monitored regularly in specialist clinics for their growth, development and organ function so that active management may be considered before organ failure develops. Referral for specialist assessment should be made if puberty is delayed beyond 14 years in girls or 14.5 years in boys.[6]

  • Parental and patient education:
    • Avoiding situations that can precipitate crises, eg cold, dehydration, and exhaustion, and early recognition and treatment of infection.
    • Palpation for splenic size to ensure early presentation of splenic sequestration can significantly reduce deaths.
    • All patients should be advised to avoid alcohol because of its dehydrating effects and smoking because it may cause the acute sickle chest syndrome.
  • Folic acid supplementation may be required. Zinc supplementation should also be considered if growth is retarded. Vitamin D deficiency is very prevalent in non-white children in the UK and may co-exist with sickle cell disease, so advice should be given regarding vitamin supplementation.[6]
  • Psychological:
  • Infection:
    • Oral penicillin prophylaxis is started at diagnosis. The risk of pneumoccocal infection remains high but decreases with age. There is a steady rise in prevalence of penicillin-resistant pneumococci.
    • Immunisation with pneumococcal, meningococcal and haemophilus vaccines.
    • Yearly influenza vaccination is also recommended.[2]
    • Hepatitis A and B immunisations are recommended for those receiving regular transfusions.[6]
    • Infection and dehydration should be treated promptly and aggressively if necessary.
  • Blood transfusions:
    • Transfusion may be required for severe anaemia or to reduce the proportion of HbS if there are lung or central nervous system complications.
    • Partial exchange transfusion (rather than top-up transfusion) is indicated when it is necessary to reduce the percentage of haemoglobin S quickly in acute life-threatening complications, such as severe acute chest syndrome, acute stroke, multi-organ failure or urgent preparation for major surgery.[6]
    • Iron overload is a possible complication of regular transfusions and iron chelation should be started in all children receiving regular blood transfusions.[6]
  • Hydroxycarbamide (hydroxyurea):
    • Many cytotoxic drugs increase fetal haemoglobin concentrations, which is potentially beneficial for patients with sickle-cell disease. Benefits include increasing haemoglobin concentrations, and decreasing platelet and white cell counts.[1]
    • Concerns remain about its myelosuppressive and teratogenic effects and its possible long-term toxicity. Hydroxycarbamide (hydroxyurea) should be stopped at least three months before conception.[11]
    • Hydroxyurea can reduce the frequency of crises in sickle cell disease, can reduce the episodes of acute chest syndrome,[6] and reduce the need for blood transfusions. It is not yet licensed for use in sickle cell disease. It should still be used only on a named patient basis with close haematological supervision.
  • Bone marrow transplantation:[1]
    • Haemopoietic cell transplantation is the only curative treatment.
    • Haemopoietic cell transplantation is only considered when serious complications have occurred, especially in children with cerebrovascular disease who are transfusion-dependent.
    • Data indicate overall survival of 92-94%, event-free survival of 82-86%, and a transplant-related mortality of 7%.
  • Stroke:[2]
    • Stroke prevention: it is recommended that transcranial Doppler ultrasonography be performed annually in children aged 2-16 years with sickle cell disease and that regular blood transfusions should be considered in those with abnormal findings on transcranial Doppler ultrasonography.
    • Assessment and prevention of nocturnal hypoxia (obstructive sleep apnoea) when relevant may be important in preventing strokes.
    • Exchange transfusion should be performed when a stroke occurs. Stroke is considered an indication for bone marrow transplantation in children and adolescents who have siblings with identical HLA.
  • Treatment of acute chest syndrome:[2]
    • Treatment includes inspired oxygen, incentive spirometry (also used for pain crises with back or chest pain), continuous positive airways pressure and exchange transfusion. Occasionally ventilation may be necessary.
    • Antibiotics are given using a combination of a macrolide with intravenous cephalosporin.
    • Transfusion or exchange transfusion produced improvements in several uncontrolled studies.
    • Hydroxycarbamide decreased the episodes of acute chest syndrome in one multicentre study.
    • Periodic transfusion is also effective in preventing recurrences.
  • Treatment of priapism:[6]
    • Priapism is an emergency requiring hydration and analgesia.
    • In minor episodes, bladder emptying, exercise such as jogging, warm baths and analgesia may help abort an attack.
    • Oral etilefrine may reduce the frequency of stuttering priapism.
    • In a prolonged episode, aspiration and irrigation of the corpora cavernosa with epinephrine or etilefrine is now the treatment of choice.
    • Children and their carers should be advised to seek treatment early and should attend hospital as an emergency if priapism persists for more than two hours.
  • Contraception:
    • Hormone and barrier methods are all acceptable choices but intrauterine devices are not recommended, as they may be associated with uterine bleeding and infection.
    • Depot contraceptive (Depo-Provera®) is safe and has been found to improve the blood picture and reduce pain crises.[12]

Painful crises

  • Pain experienced in a vaso-occlusive crisis results from oxygen deprivation of tissues and avascular necrosis of the bone marrow.
  • Dactylitis is a common early manifestation that may occur before the age of 6 months.[2]
  • The risk of vaso-occlusive episodes is increased by exposure to cold, fever, and dehydration.
  • Over 90% of hospital admissions for patients with sickle cell disease are for painful crises, but nearly all sickle pain is coped with in the community.
  • Pain has been reported to occur on up to 30% of days with a loss of 10% of schooldays in children.
  • Hydroxycarbamide can reduce the frequency of painful crises in sickle cell disease (unlicensed indication in the UK).[13]
  • Management:
    • Avoid exposure to cold, fever, dehydration and stress.
    • Most episodes coped with at home respond to simple oral analgesia, increased fluid intake, warmth and rest.
    • A simple analgesic ladder is appropriate, starting with paracetamol and/or ibuprofen.[6] If necessary, use weak opioids, eg codeine or dextropropoxyphene, for patients with mild pain.[2]
    • Always look for a cause, eg infection.[2]
    • Admit patients if pain does not subside promptly, if there is a need for strong opioid treatment, or if there is fever, pallor or signs of respiratory compromise.[2]
    • Benzodiazepines may be helpful to reduce anxiety.[2]

Pregnancy[11]

Pregnant women with sickle cell disease must be monitored by an obstetrician and a specialist in the disease working closely together. Fetuses are at increased risk of prematurity, low birth weight and death.

  • Worsening anaemia, vaso-occlusive crises, and acute chest syndrome may occur during pregnancy.[2]
  • Women with sickle cell disease should be considered for low-dose aspirin 75 mg once daily from 12 weeks of gestation in an effort to reduce the risk of developing pre-eclampsia.
  • Women with sickle cell disease should be advised to receive prophylactic low molecular weight heparin during antenatal hospital admissions.
  • Routine prophylactic transfusion is not recommended during pregnancy for women with sickle cell disease. If an acute exchange transfusion is required for the treatment of a sickle complication, it may be appropriate to continue the transfusion regimen for the remainder of the pregnancy.
  • See Management of Sickle Cell Disease in Pregnancy under 'Document references', below, for further guidance on the care of women with sickle cell disease in pregnancy.[11]

General anaesthesia[2]

  • Patients with sickle cell disease are at high risk of perioperative complications, especially acute chest syndrome and pain.
  • Preoperative transfusion may decrease the risk of postoperative complications.

Travel advice

  • Increased fluid intake, abstinence from alcohol, and physical movement during travel, including flights, are helpful.
  • Appropriate antimalarial prophylaxis is essential for patients travelling to areas at risk of malaria.
  • Emphasis on a bacteriologically clean drinking water supply. Patients should increase their oral fluid intake above the standard 3 L/day for adults when they are in hot climates, to compensate for the increased insensible losses.
  • Sickle cell disease is very variable in its manifestations. The pattern of organ involvement alters with age.
  • Infection: patients are prone to infection, especially pneumococcus, typhoid osteomyelitis and haemophilus because of hyposplenism resulting from sickling and consequent autosplenectomy.
  • Stroke: clinical evidence of stroke occurs by age 20 years in 11% of patients with sickle cell disease.[2]
  • Priapism: males with sickle cell disease may experience painful erections, which may be brief but recurrent or may last six hours or more and can lead to impotence.[2]
  • Cardiac failure: left-sided heart disease occurs in about 13% of adults with sickle-cell disease and is mainly caused by diastolic dysfunction, which is an independent risk factor for mortality.[1]
  • Chronic pulmonary disease usually develops in patients older than 30 years. Cor pulmonale may develop. Pulmonary hypertension occurs in about 30% of adults with sickle cell disease and is associated with high rates of leg ulcer, priapism, and renal dysfunction.[2]
  • Gallstones caused by chronic haemolytic anaemia.
  • Eye: retinopathy, retinal infarcts, retinal haemorrhage and retinal detachment.
  • Transfusion complications: alloimmunisation, exposure to possible infections, risk of iron overload and consequent organ damage.
  • Chronic leg ulcers: may become infected.
  • Avascular necrosis: often in the femoral head and humeral head.
  • Chronic organ damage: vaso-occlusion, hyperhaemolysis, and increased blood viscosity are major causes of chronic organ damage (osteonecrosis, liver failure, renal failure, leg ulcer, retinopathy), which is very variable in severity.[2]
  • Chronic kidney disease:[14]
    • Occurs in up to 5% of patients with sickle cell anaemia.
    • Causes a worsening anaemia.
    • Patients may require treatment with high doses of erythropoietin.
  • Learning difficulties:
    • Subtle, but important and widespread, neuropsychological defects result from sickle cell disease and may be present even in the absence of overt neurological complications.
    • This damage is probably responsible for the decreased intellectual ability of about five points in IQ in patients with sickle cell disease compared with controls.
    • This reduction indicates a twofold risk for significant learning difficulties and the need for remedial education compared with their peers.
  • Clinical severity and prognosis are very variable, ranging from survival into the 60s and 70s to a severe disease with substantial organ damage and early death.[2]
  • Since 1973, the average lifespan of a patient with sickle cell disease has increased from 14 years to 50 years.[14]
  • The most common causes of death are pulmonary complications, cerebrovascular accidents, causes related to infection, acute splenic sequestration, and chronic organ damage and failure.
  • Three prognostic factors have been identified as predictors of an adverse outcome: hand-foot syndrome (dactylitis) in infants younger than 1 year, Hb less than 7 g/dL, and leukocytosis in the absence of infection.[7]

Further reading & references

  1. Rees DC, Williams TN, Gladwin MT; Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31. Epub 2010 Dec 3.
  2. de Montalembert M; Management of sickle cell disease. BMJ. 2008 Sep 8;337:a1397. doi: 10.1136/bmj.a1397.
  3. Stuart MJ, Nagel RL; Sickle-cell disease. Lancet. 2004 Oct 9-15;364(9442):1343-60.
  4. Tsaras G, Owusu-Ansah A, Boateng FO, et al; Complications associated with sickle cell trait: a brief narrative review. Am J Med. 2009 Jun;122(6):507-12. Epub 2009 Apr 24.
  5. Scheinin L, Wetli CV; Sudden death and sickle cell trait: medicolegal considerations and implications. Am J Forensic Med Pathol. 2009 Jun;30(2):204-8.
  6. Sickle cell disease in childhood : various standards and guidelines for clinical care, NHS Sickle Cell & Thalassaemia Screening Programme, NHS England (various dates)
  7. Maakaron JE et al, Sickle Cell Anemia, Medscape, Jan 2012
  8. Significant haemoglobinopathies: guidelines for screening and diagnosis, British Committee for Standards in Haematology (September 2009)
  9. Sickle Cell & Thalassaemia screening across the UK; National Screening Portal
  10. Sickle Cell Anemia, Online Mendelian Inheritance in Man (OMIM)
  11. Management of Sickle Cell Disease in Pregnancy, Royal College of Obstetricians and Gynaecologists (August 2011)
  12. Manchikanti A, Grimes DA, Lopez LM, et al; Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD006261.
  13. Ballas SK, Bauserman RL, McCarthy WF, et al; Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital J Pain Symptom Manage. 2010 Sep 21.
  14. Claster S, Vichinsky EP; Managing sickle cell disease BMJ 2003;327:1151-1155

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Naomi Hartree
Current Version:
Peer Reviewer:
Dr Hannah Gronow
Last Checked:
20/02/2012
Document ID:
2779 (v23)
© EMIS